Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $44.6667.

A number of brokerages recently commented on TYRA. Cantor Fitzgerald initiated coverage on Tyra Biosciences in a report on Tuesday, February 24th. They set an “overweight” rating for the company. HC Wainwright boosted their price target on shares of Tyra Biosciences from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Piper Sandler increased their price target on shares of Tyra Biosciences from $42.00 to $56.00 and gave the stock an “overweight” rating in a research report on Friday, March 20th. Barclays began coverage on shares of Tyra Biosciences in a research note on Tuesday, January 27th. They issued an “overweight” rating for the company. Finally, William Blair initiated coverage on shares of Tyra Biosciences in a report on Tuesday, February 10th. They issued an “outperform” rating for the company.

Insider Buying and Selling

In other Tyra Biosciences news, Director Gilla Kaplan sold 14,295 shares of the firm’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the completion of the transaction, the director owned 28,231 shares of the company’s stock, valued at $1,043,700.07. This trade represents a 33.61% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 15.20% of the stock is owned by corporate insiders.

Institutional Trading of Tyra Biosciences

Several hedge funds have recently modified their holdings of the stock. Commodore Capital LP boosted its stake in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock valued at $29,667,000 after buying an additional 2,150,000 shares during the period. Farallon Capital Management LLC increased its stake in shares of Tyra Biosciences by 80.7% during the fourth quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after buying an additional 923,000 shares during the period. Caligan Partners LP increased its stake in shares of Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after buying an additional 506,875 shares during the period. Boone Capital Management LLC acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $10,476,000. Finally, Elmind Capital LP acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $9,202,000. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Down 0.1%

NASDAQ:TYRA opened at $38.28 on Thursday. The stock’s fifty day moving average is $33.36 and its two-hundred day moving average is $24.29. Tyra Biosciences has a 52 week low of $6.42 and a 52 week high of $40.65. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -19.04 and a beta of 0.96.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). On average, sell-side analysts expect that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.